Cristina SÃnchez

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3079101/publications.pdf

Version: 2024-02-01

52	4,916	136950	206112
papers	citations	32 h-index	48 g-index

53	53	53	6082
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Glycosylation of Epigallocatechin Gallate by Engineered Glycoside Hydrolases from Talaromyces amestolkiae: Potential Antiproliferative and Neuroprotective Effect of These Molecules. Antioxidants, 2022, 11, 1325.	5.1	5
2	Transglycosylation products generated by Talaromyces amestolkiae GH3 Î²-glucosidases: effect of hydroxytyrosol, vanillin and its glucosides on breast cancer cells. Microbial Cell Factories, 2019, 18, 97.	4.0	28
3	Therapeutic targeting of HER2â€“CB ₂ R heteromers in HER2-positive breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 3863-3872.	7.1	40
4	Appraising the â€œentourage effectâ€• Antitumor action of a pure cannabinoid versus a botanical drug preparation in preclinical models of breast cancer. Biochemical Pharmacology, 2018, 157, 285-293.	4.4	126
5	Loss of Cannabinoid CB₁Receptors Induces Cortical Migration Malformations and Increases Seizure Susceptibility. Cerebral Cortex, 2017, 27, 5303-5317.	2.9	23
6	In situ localization of tumor cells associated with the epithelial-mesenchymal transition marker Snail and the prognostic impact of lymphocytes in the tumor microenvironment in invasive ductal breast cancer. Experimental and Molecular Pathology, 2017, 102, 268-275.	2.1	8
7	Anticancer Mechanisms of Cannabinoids. Current Oncology, 2016, 23, 23-32.	2.2	192
8	Activation of the orphan receptor GPR55 by lysophosphatidylinositol promotes metastasis in triple-negative breast cancer. Oncotarget, 2016, 7, 47565-47575.	1.8	40
9	Selective, Nontoxic CB₂ Cannabinoid o-Quinone with in Vivo Activity against Triple-Negative Breast Cancer. Journal of Medicinal Chemistry, 2015, 58, 2256-2264.	6.4	33
10	Efficient in vivo antitumor effect of an immunotoxin based on ribotoxin Î±-sarcin in nude mice bearing human colorectal cancer xenografts. SpringerPlus, 2015, 4, 168.	1.2	26
11	New Inhibitors of Angiogenesis with Antitumor Activity in Vivo. Journal of Medicinal Chemistry, 2015, 58, 3757-3766.	6.4	18
12	Role of Cannabinoid Receptor CB2 in HER2 Pro-oncogenic Signaling in Breast Cancer. Journal of the National Cancer Institute, 2015, 107, djv077.	6.3	98
13	Endocannabinoids and Cancer. Handbook of Experimental Pharmacology, 2015, 231, 449-472.	1.8	45
14	Loss of Tribbles pseudokinase-3 promotes Akt-driven tumorigenesis via FOXO inactivation. Cell Death and Differentiation, 2015, 22, 131-144.	11.2	70
15	TRIB3 suppresses tumorigenesis by controlling mTORC2/AKT/FOXO signaling. Molecular and Cellular Oncology, 2015, 2, e980134.	0.7	16
16	Dopamine DRD2/ANKK1 Taq1A and DAT1 VNTR polymorphisms are associated with a cognitive flexibility profile in pathological gamblers. Journal of Psychopharmacology, 2014, 28, 1170-1177.	4.0	28
17	Targeting CB2-GPR55 Receptor Heteromers Modulates Cancer Cell Signaling. Journal of Biological Chemistry, 2014, 289, 21960-21972.	3.4	95
18	The orphan receptor GPR55 drives skin carcinogenesis and is upregulated in human squamous cell carcinomas. Oncogene, 2013, 32, 2534-2542.	5.9	81

#	Article	IF	Citations
19	The Role of GPR55 in Cancer. , 2013, , 115-133.		1
20	Cannabinoids: A new hope for breast cancer therapy?. Cancer Treatment Reviews, 2012, 38, 911-918.	7.7	88
21	Towards the use of cannabinoids as antitumour agents. Nature Reviews Cancer, 2012, 12, 436-444.	28.4	303
22	The orphan G protein-coupled receptor GPR55 promotes cancer cell proliferation via ERK. Oncogene, 2011, 30, 245-252.	5.9	160
23	Minireview: Recent Developments in the Physiology and Pathology of the Lysophosphatidylinositol-Sensitive Receptor GPR55. Molecular Endocrinology, 2011, 25, 1835-1848.	3.7	140
24	Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition. Molecular Cancer, 2010, 9, 196.	19.2	156
25	JunD is involved in the antiproliferative effect of Î”9-tetrahydrocannabinol on human breast cancer cells. Oncogene, 2008, 27, 5033-5044.	5.9	66
26	Targeting Cannabinoid Receptors in Brain Tumors. , 2008, , 361-374.		1
27	Cannabinoids and Gliomas. Molecular Neurobiology, 2007, 36, 60-67.	4.0	82
28	A pilot clinical study of Î”9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. British Journal of Cancer, 2006, 95, 197-203.	6.4	287
29	Î”9-Tetrahydrocannabinol Inhibits Cell Cycle Progression in Human Breast Cancer Cells through Cdc2 Regulation. Cancer Research, 2006, 66, 6615-6621.	0.9	192
30	Cannabinoids and ceramide: Two lipids acting hand-by-hand. Life Sciences, 2005, 77, 1723-1731.	4.3	69
31	Genetic diversity of 15 STRs in Choles from northeast of Chiapas (Mexico). Journal of Forensic Sciences, 2005, 50, 1499-501.	1.6	4
32	Hypothesis: cannabinoid therapy for the treatment of gliomas?. Neuropharmacology, 2004, 47, 315-323.	4.1	70
33	Anandamide Enhances Extracellular Levels of Adenosine and Induces Sleep: An In Vivo Microdialysis Study. Sleep, 2003, 26, 943-947.	1.1	98
34	De novo-synthesized ceramide is involved in cannabinoid-induced apoptosis. Biochemical Journal, 2002, 363, 183.	3.7	145
35	De novo-synthesized ceramide is involved in cannabinoid-induced apoptosis. Biochemical Journal, 2002, 363, 183-188.	3.7	144
36	Cannabinoids and cell fate. , 2002, 95, 175-184.		148

#	Article	IF	Citations
37	Evidence for the Lack of Involvement of Sphingomyelin Hydrolysis in the Tumor Necrosis Factor-Induced Secretion of Nerve Growth Factor in Primary Astrocyte Cultures. Journal of Neurochemistry, 2002, 71, 498-505.	3.9	10
38	Ceramide Signaling in Cannabinoid Action. Molecular Biology Intelligence Unit, 2002, , 125-132.	0.2	0
39	Ceramide: a new second messenger of cannabinoid action. Trends in Pharmacological Sciences, 2001, 22, 19-22.	8.7	115
40	The CB₁ Cannabinoid Receptor of Astrocytes Is Coupled to Sphingomyelin Hydrolysis through the Adaptor Protein Fan. Molecular Pharmacology, 2001, 59, 955-959.	2.3	98
41	Control of the cell survival/death decision by cannabinoids. Journal of Molecular Medicine, 2001, 78, 613-625.	3.9	207
42	The Stimulation of Ketogenesis by Cannabinoids in Cultured Astrocytes Defines Carnitine Palmitoyltransferase I as a New Ceramide-Activated Enzyme. Journal of Neurochemistry, 2001, 72, 1759-1768.	3.9	72
43	Signaling at zero g: a comment. Trends in Biochemical Sciences, 2001, 26, 533.	7.5	1
44	Anti-tumoral action of cannabinoids: Involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nature Medicine, 2000, 6, 313-319.	30.7	610
45	Effects of cannabinoids on energy metabolism. Life Sciences, 1999, 65, 657-664.	4.3	63
46	Î”9-Tetrahydrocannabinol induces apoptosis in C6 glioma cells. FEBS Letters, 1998, 436, 6-10.	2.8	248
47	Involvement of Sphingomyelin Hydrolysis and the Mitogen-Activated Protein Kinase Cascade in the Î”⁹-Tetrahydrocannabinol-Induced Stimulation of Glucose Metabolism in Primary Astrocytes. Molecular Pharmacology, 1998, 54, 834-843.	2.3	189
48	Role of Carnitine Palmitoyltransferase I in the Control of Ketogenesis in Primary Cultures of Rat Astrocytes. Journal of Neurochemistry, 1998, 71, 1597-1606.	3.9	88
49	Metabolic stimulation of mouse spleen lymphocytes by low doses of 9-tetrahydrocannabinol. Life Sciences, 1997, 60, 1709-1717.	4.3	15
50	Î”9-Tetrahydrocannabinol stimulates glucose utilization in C6 glioma cells. Brain Research, 1997, 767, 64-71.	2.2	33
51	Are Cytoskeletal Components Involved in the Control of Hepatic Carnitine Palmitoyltransferase I Activity?. Biochemical and Biophysical Research Communications, 1996, 224, 754-759.	2.1	21
52	Effects of anandamide on hepatic fatty acid metabolism. Biochemical Pharmacology, 1995, 50, 885-888.	4.4	18